The Role of PPARγ in Lung Cancer and COX-2 Pathway
Author Information
Author(s): Saswati Hazra, Katherine A. Peebles, Sherven Sharma, Jenny T. Dubinett, Steven M.
Primary Institution: UCLA Lung Cancer Research Program, Division of Pulmonary and Critical Care Medicine and Hospitalists, Department of Medicine, Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Hypothesis
How do PPARγ and COX-2 pathways interact in lung cancer?
Conclusion
PPARγ activation may reduce COX-2 levels and tumor progression in lung cancer.
Supporting Evidence
- Decreased PPARγ expression is linked to poor prognosis in lung cancer patients.
- PPARγ agonists can inhibit growth of non-small-cell lung cancer cells.
- COX-2 overexpression is frequently observed in non-small-cell lung cancer.
- PPARγ activation may reduce COX-2 levels through various mechanisms.
- Certain TZDs can decrease PGE2 production in lung cancer cells.
Takeaway
This study looks at how a protein called PPARγ can help fight lung cancer by lowering another protein called COX-2 that makes tumors grow.
Methodology
The review summarizes various studies on PPARγ and COX-2 interactions in lung cancer.
Limitations
The review is based on existing studies and may not include all recent findings.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website